Development of ferroptosis inhibitors for Huntington Disease

亨廷顿病铁死亡抑制剂的开发

• 批准号: 10445418
• 负责人: Brent R Stockwell
• 金额: $ 38.96万
• 依托单位: COLUMBIA UNIV NEW YORK MORNINGSIDE
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-08-15 至 2023-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10445418
• 关键词: Development; ferroptosis; inhibitors; Huntington; Disease

Project Summary Ferrostatin is a potent inhibitor of ferroptosis; which is a non-apoptotic form of cell death potentially involved in a number of degenerative diseases. We have shown the effectiveness of Fer-1 in brain slice models of Huntington's disease (HD) and glutamate toxicity. However, ferrostatin's pharmacokinetic/pharmacodynamic (PK/PD) properties make it unsuitable for use in animal models to further test the role of ferroptosis in these diseases. We have made a series of ferrostatin analogs to explore ferrostatin's structure-activity relationship (SAR) and to improve activity and metabolic and plasma stability. While we have made significant progress in creating metabolically stable analogs with good potency and plasma stability, additional improvements are envisioned that could result in highly potent, stable compounds that could be dosed in vivo. The result of this investigation will be a set of optimized compounds for in vivo use to study the role of lipid peroxidation in a mouse model of Huntington Disease. In the longer term, we will be able to use these optimized compounds to probe the role of lipid peroxidation and ferroptosis in a variety of degenerative diseases.

项目摘要 铁抑素是铁凋亡的有效抑制剂;铁凋亡是一种非凋亡形式的细胞死亡，可能参与细胞凋亡。 一些退化性疾病。我们已经证明了Fer-1在脑切片模型中的有效性， 亨廷顿病（HD）和谷氨酸毒性。然而，铁抑素的药代动力学/药效学 (PK/PD）性质使得其不适合用于动物模型中以进一步测试铁凋亡在这些疾病中的作用。 疾病我们合成了一系列的铁抑素类似物，以探讨铁抑素的构效关系 (SAR)并改善活性、代谢和血浆稳定性。虽然我们在以下方面取得了重大进展 产生具有良好效力和血浆稳定性的代谢稳定的类似物，另外的改进是 设想可以产生可以在体内给药的高效、稳定的化合物。这样做的结果 研究将是一组优化的化合物，用于体内研究脂质过氧化作用， 亨廷顿病的小鼠模型。从长远来看，我们将能够使用这些优化的化合物， 探讨脂质过氧化和铁凋亡在各种退行性疾病中的作用。